tezepelumab severe asthma
Selected indexed studies
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. (N Engl J Med, 2021) [PMID:33979488]
- Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles. (Respir Res, 2024) [PMID:39385131]
- Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. (J Asthma Allergy, 2024) [PMID:38524099]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. (2021) pubmed
- Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles. (2024) pubmed
- Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. (2024) pubmed
- Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. (2023) pubmed
- NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. (2020) pubmed
- PMID:40127163 (2023) pubmed
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. (2025) pubmed
- Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. (2022) pubmed
- Positioning of Tezepelumab in Severe Asthma. (2024) pubmed
- Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. (2021) pubmed